Ahmet Afsin Oktay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmet Afsin Oktay has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Annabelle Santos Volgman
Division of Cardiology, Rush University Medical Center, Chicago, IL, USA
2 shared publicationsCarl J. Lavie
Ochsner Clinical School, John Ochsner Heart and Vascular Institute, The University of Queensland School of Medicine, New Orleans, USA
2 shared publications- Henry Okoroike
Rush University Medical Center
2 shared publications Manvita Tatavarthy
Department of Medicine, Rush University Medical Center, Chicago, IL, USA
2 shared publications- Ali Serdar Fak
Division of General Internal Medicine, Department of Internal Medicine, Marmara University Faculty of Medicine, İstanbul, Turkey
1 shared publication Aum Solanki
Division of Cardiology, Rush University Medical Center, Chicago, IL, USA
1 shared publication
Latest Publications
- Open Access
- 3 September 2026
- Published by Elsevier in The American Journal of Cardiology
- Vol. 278, 70-74
Early Low-Density Lipoprotein Cholesterol Target Attainment Is Associated With Fewer Recurrent Cardiovascular Events After Acute Myocardial Infarction: A Real-World Cohort Study
- 3 September 2026
- Published by Elsevier in The American Journal of Cardiology
- Vol. 278, 70-74
Open AccessEarly Low-Density Lipoprotein Cholesterol Target Attainment Is Associated With Fewer Recurrent Cardiovascular Events After Acute Myocardial Infarction: A Real-World Cohort Study
- Open Access
- 2 June 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 756-775
Hypertension and left ventricular geometry: Diagnosis, prognosis, and management
Hypertension remains one of the most prevalent and consequential cardiovascular risk factors worldwide and is a leading cause of heart disease. Hypertensive heart disease may manifest in alterations in left ventricular (LV) geometry, including concentric remodeling, concentric hypertrophy, and eccentric hypertrophy, representing adaptive responses to chronic pressure or volume overload that may progress to maladaptive remodeling and heart failure. LV geometric patterns, defined by LV mass and relative wall thickness, carry important diagnostic and prognostic implications independent of blood pressure levels. This review provides a comprehensive and contemporary overview of the relationship between hypertension and LV geometry. We summarize key determinants of hypertensive LV remodeling, including cumulative blood pressure exposure, sex differences, metabolic comorbidities, obesity, pericardial adiposity, and obstructive sleep apnea. We discuss current approaches to screening and diagnosis, highlighting the strengths and limitations of electrocardiography, echocardiography, and cardiac magnetic resonance imaging. We review emerging applications of artificial intelligence in electrocardiographic and echocardiographic assessment, with particular attention to their potential to improve detection, phenotypic differentiation, and prognostication. We further examine the prognostic significance of LV remodeling in hypertension and review evidence supporting regression of LV hypertrophy through intensive blood pressure control, management of comorbidities, and lifestyle interventions. Early identification and reversal of hypertensive LV remodeling may offer a critical opportunity to prevent progression to heart failure and reduce long-term cardiovascular morbidity and mortality.
- 2 June 2026
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 25, 756-775
Open AccessHypertension and left ventricular geometry: Diagnosis, prognosis, and management
Hypertension remains one of the most prevalent and consequential cardiovascular risk factors worldwide and is a leading cause of heart disease. Hypertensive heart disease may manifest in alterations in left ventricular (LV) geometry, including concentric remodeling, concentric hypertrophy, and eccentric hypertrophy, representing adaptive responses to chronic pressure or volume overload that may progress to maladaptive remodeling and heart failure. LV geometric patterns, defined by LV mass and relative wall thickness, carry important diagnostic and prognostic implications independent of blood pressure levels. This review provides a comprehensive and contemporary overview of the relationship between hypertension and LV geometry. We summarize key determinants of hypertensive LV remodeling, including cumulative blood pressure exposure, sex differences, metabolic comorbidities, obesity, pericardial adiposity, and obstructive sleep apnea. We discuss current approaches to screening and diagnosis, highlighting the strengths and limitations of electrocardiography, echocardiography, and cardiac magnetic resonance imaging. We review emerging applications of artificial intelligence in electrocardiographic and echocardiographic assessment, with particular attention to their potential to improve detection, phenotypic differentiation, and prognostication. We further examine the prognostic significance of LV remodeling in hypertension and review evidence supporting regression of LV hypertrophy through intensive blood pressure control, management of comorbidities, and lifestyle interventions. Early identification and reversal of hypertensive LV remodeling may offer a critical opportunity to prevent progression to heart failure and reduce long-term cardiovascular morbidity and mortality.
- Open Access
- 2 June 2026
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 8 (2) , 96-101
Validation of a novel Guideline Directed Medical Therapy (GDMT) scoring tool to optimize therapy for patients with heart failure with reduced ejection fraction (HFrEF)
Background: The mortality benefit of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) is well established. However, contemporary registry data consistently demonstrates substantial gaps in GDMT optimization. A standardized tool to quantify GDMT optimization and target dose achievement may help identify treatment deficits, guide clinical decision-making, and improve associated patient outcomes. Methods: This retrospective, single-center observational study evaluated the internal validity of a novel GDMT scoring tool to quantify GDMT optimization. Adult patients admitted between September 2022 and September 2023 with HFrEF and outpatient follow-up were included. The primary analysis assessed the association between GDMT optimization at 30 days and the risk of 90-day all-cause hospitalization using multivariable logistic regression. Secondary analyses described GDMT optimization rates at 30 days, quadruple therapy rates, and associations between GDMT optimization and 90-day HF hospitalization and all-cause mortality. Results: Eighty-nine patients met inclusion criteria. At 30 days, 76% of patients (n= 68) achieved a GDMT score of ≥ 5 and 24% (n= 21) had a suboptimal GDMT score of P=0.008 ) though no significant differences were observed for HF hospitalizations (OR 0.55 CI 0.17-1.85, P=0.33 ) or all-cause mortality ( P=0.997 ). Conclusion: An optimized GDMT score of ≥ 5 at 30 days was associated with reduced odds of all-cause readmissions at 90 days ( P=0.008 ).
- 2 June 2026
- Published by Wolters Kluwer Health in Annals of Clinical Cardiology
- Vol. 8 (2) , 96-101
Open AccessValidation of a novel Guideline Directed Medical Therapy (GDMT) scoring tool to optimize therapy for patients with heart failure with reduced ejection fraction (HFrEF)
Background: The mortality benefit of guideline-directed medical therapy (GDMT) for patients with heart failure with reduced ejection fraction (HFrEF) is well established. However, contemporary registry data consistently demonstrates substantial gaps in GDMT optimization. A standardized tool to quantify GDMT optimization and target dose achievement may help identify treatment deficits, guide clinical decision-making, and improve associated patient outcomes. Methods: This retrospective, single-center observational study evaluated the internal validity of a novel GDMT scoring tool to quantify GDMT optimization. Adult patients admitted between September 2022 and September 2023 with HFrEF and outpatient follow-up were included. The primary analysis assessed the association between GDMT optimization at 30 days and the risk of 90-day all-cause hospitalization using multivariable logistic regression. Secondary analyses described GDMT optimization rates at 30 days, quadruple therapy rates, and associations between GDMT optimization and 90-day HF hospitalization and all-cause mortality. Results: Eighty-nine patients met inclusion criteria. At 30 days, 76% of patients (n= 68) achieved a GDMT score of ≥ 5 and 24% (n= 21) had a suboptimal GDMT score of P=0.008 ) though no significant differences were observed for HF hospitalizations (OR 0.55 CI 0.17-1.85, P=0.33 ) or all-cause mortality ( P=0.997 ). Conclusion: An optimized GDMT score of ≥ 5 at 30 days was associated with reduced odds of all-cause readmissions at 90 days ( P=0.008 ).
- 18 December 2025
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (3) , 103249
Challenges in the diagnosis and management of hypertrophic cardiomyopathy and the promise of artificial intelligence
- 18 December 2025
- Published by Elsevier in Current Problems in Cardiology
- Vol. 51 (3) , 103249
Challenges in the diagnosis and management of hypertrophic cardiomyopathy and the promise of artificial intelligence
- 7 June 2025
- Published by Springer Nature in Current Diabetes Reports
- Vol. 25 (1) , 1-11
The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus
Purpose of Review The “obesity paradox” describes the counterintuitive observation that overweight and mildly obese individuals with cardiovascular disease (CVD) may have better outcomes than those with normal weight. This paradox is particularly intriguing in patients with type-2 diabetes (T2D), where obesity is a well-established risk factor for cardiometabolic complications. Recent Findings Evidence from some epidemiological studies suggested an obesity paradox in mortality risk among patients with T2D. However, confounding factors may influence this association, including reverse causality, differences in risk factor profiles, and adipose tissue distribution. Recent research also questions the reliance on body mass index as an accurate measure of metabolic health, emphasizing the role of alternative anthropometric indices. Summary This review critically evaluates the evidence for the obesity paradox in T2D, explores potential mechanistic explanations, and discusses clinical implications. Understanding the complex interaction between diabetes and obesity in CVD risk is essential for refining obesity management strategies in individuals with T2D and CVD.
- 7 June 2025
- Published by Springer Nature in Current Diabetes Reports
- Vol. 25 (1) , 1-11
The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus
Purpose of Review The “obesity paradox” describes the counterintuitive observation that overweight and mildly obese individuals with cardiovascular disease (CVD) may have better outcomes than those with normal weight. This paradox is particularly intriguing in patients with type-2 diabetes (T2D), where obesity is a well-established risk factor for cardiometabolic complications. Recent Findings Evidence from some epidemiological studies suggested an obesity paradox in mortality risk among patients with T2D. However, confounding factors may influence this association, including reverse causality, differences in risk factor profiles, and adipose tissue distribution. Recent research also questions the reliance on body mass index as an accurate measure of metabolic health, emphasizing the role of alternative anthropometric indices. Summary This review critically evaluates the evidence for the obesity paradox in T2D, explores potential mechanistic explanations, and discusses clinical implications. Understanding the complex interaction between diabetes and obesity in CVD risk is essential for refining obesity management strategies in individuals with T2D and CVD.
- Open Access
- 10 January 2025
- Published by Wolters Kluwer Health in Heart and Mind
- Vol. 9 (1) , 61-67
Cardiovascular Benefits of Dance as a Unique Form of Exercise: A Literature Review
Physical activity has well-known benefits in improving multiple risk factors that lead to cardiovascular disease. Dance is a unique form of exercise that is often accessible and modifiable according to the individual’s cultural background and physical abilities. It can increase physical activity levels by creating social engagement. Limited data from intervention studies with small sample sizes and short duration or follow-up suggested that routine participation in dance can improve agility and balance, leading to decreased rates of immobility and depression, which may act as an independent risk factor for cardiovascular disease. It may also assist with blood pressure control in patients with hypertension. Moreover, dance training may improve cardiorespiratory symptoms in individuals with or without heart failure. Studies also suggested that culturally sensitive dance programs may enhance participation and retention of physical activity in various ethnic groups and women. Future research is needed to understand better the potential long-term cardiovascular benefits of dance training and the feasibility of implementing these programs to improve cardiovascular health in special populations.
- 10 January 2025
- Published by Wolters Kluwer Health in Heart and Mind
- Vol. 9 (1) , 61-67
Open AccessCardiovascular Benefits of Dance as a Unique Form of Exercise: A Literature Review
Physical activity has well-known benefits in improving multiple risk factors that lead to cardiovascular disease. Dance is a unique form of exercise that is often accessible and modifiable according to the individual’s cultural background and physical abilities. It can increase physical activity levels by creating social engagement. Limited data from intervention studies with small sample sizes and short duration or follow-up suggested that routine participation in dance can improve agility and balance, leading to decreased rates of immobility and depression, which may act as an independent risk factor for cardiovascular disease. It may also assist with blood pressure control in patients with hypertension. Moreover, dance training may improve cardiorespiratory symptoms in individuals with or without heart failure. Studies also suggested that culturally sensitive dance programs may enhance participation and retention of physical activity in various ethnic groups and women. Future research is needed to understand better the potential long-term cardiovascular benefits of dance training and the feasibility of implementing these programs to improve cardiovascular health in special populations.
- 5 September 2024
- Published by Springer Nature in Current Cardiology Reports
- Vol. 26 (11) , 1309-1320
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Purpose of Review Cardiovascular disease (CVD) is the leading cause of death globally and is closely associated with obesity and type 2 diabetes mellitus (T2DM). This review examines the interplay between obesity, T2DM, and CVD, highlighting the increasing prevalence and economic burden of these conditions. Recent Findings Pharmacologic therapies, particularly glucagon-like peptide-1 receptor agonists, show promise in substantial weight loss and subsequent reduction of adverse cardiovascular events in obese individuals with and without diabetes. Summary Obesity significantly contributes to the development of insulin resistance and T2DM, further escalating CVD risk. The common co-occurrence of these three conditions may involve several other pathophysiological mechanisms, such as chronic inflammation, increased visceral adiposity, and endothelial dysfunction. Until recently, lifestyle modifications and bariatric surgery had been the primary methods for weight loss and mitigating obesity-associated cardiovascular risk. Newer pharmacological options have led to a paradigm shift in our approach to obesity management as they provide substantial benefits in weight loss, glycemic control, and cardiovascular risk reduction.
- 5 September 2024
- Published by Springer Nature in Current Cardiology Reports
- Vol. 26 (11) , 1309-1320
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Purpose of Review Cardiovascular disease (CVD) is the leading cause of death globally and is closely associated with obesity and type 2 diabetes mellitus (T2DM). This review examines the interplay between obesity, T2DM, and CVD, highlighting the increasing prevalence and economic burden of these conditions. Recent Findings Pharmacologic therapies, particularly glucagon-like peptide-1 receptor agonists, show promise in substantial weight loss and subsequent reduction of adverse cardiovascular events in obese individuals with and without diabetes. Summary Obesity significantly contributes to the development of insulin resistance and T2DM, further escalating CVD risk. The common co-occurrence of these three conditions may involve several other pathophysiological mechanisms, such as chronic inflammation, increased visceral adiposity, and endothelial dysfunction. Until recently, lifestyle modifications and bariatric surgery had been the primary methods for weight loss and mitigating obesity-associated cardiovascular risk. Newer pharmacological options have led to a paradigm shift in our approach to obesity management as they provide substantial benefits in weight loss, glycemic control, and cardiovascular risk reduction.
- 4 March 2024
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 39 (4) , 251-258
Prevention and treatment of hypertensive left ventricular hypertrophy
Purpose of review: Left ventricular (LV) hypertrophy (LVH) is a well recognized target organ adaptation to longstanding uncontrolled hypertension and other cardiovascular risk factors. It is also a strong and independent predictor of many cardiovascular disorders. Recent findings: This focused review explores the current concepts in screening, diagnosis, prevention, and treatment of LVH in patients with hypertension. Currently, the primary screening and diagnostic tools for LVH are ECG and 2D echocardiography. Implementing machine learning in the diagnostic modalities can improve sensitivity in the detection of LVH. Lifestyle modifications, blood pressure control with antihypertensive therapy, and management of comorbidities aid in preventing and reversing LV remodeling. Summary: LVH is a common and often silent complication of hypertension. Prevention and reversal of LV remodeling are crucial for cardiovascular risk reduction in patients with hypertension.
- 4 March 2024
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 39 (4) , 251-258
Prevention and treatment of hypertensive left ventricular hypertrophy
Purpose of review: Left ventricular (LV) hypertrophy (LVH) is a well recognized target organ adaptation to longstanding uncontrolled hypertension and other cardiovascular risk factors. It is also a strong and independent predictor of many cardiovascular disorders. Recent findings: This focused review explores the current concepts in screening, diagnosis, prevention, and treatment of LVH in patients with hypertension. Currently, the primary screening and diagnostic tools for LVH are ECG and 2D echocardiography. Implementing machine learning in the diagnostic modalities can improve sensitivity in the detection of LVH. Lifestyle modifications, blood pressure control with antihypertensive therapy, and management of comorbidities aid in preventing and reversing LV remodeling. Summary: LVH is a common and often silent complication of hypertension. Prevention and reversal of LV remodeling are crucial for cardiovascular risk reduction in patients with hypertension.
- 25 August 2022
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 20 (9) , 707-717
The complex interplay between diabetes mellitus and atrial fibrillation
: A growing body of evidence suggests that diabetes mellitus (DM) is associated with an increased risk of new-onset atrial fibrillation (AF) and contributes to suboptimal arrhythmia control and poo...
- 25 August 2022
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 20 (9) , 707-717
The complex interplay between diabetes mellitus and atrial fibrillation
: A growing body of evidence suggests that diabetes mellitus (DM) is associated with an increased risk of new-onset atrial fibrillation (AF) and contributes to suboptimal arrhythmia control and poo...
- 16 July 2022
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 32 (8) , 476-478
Editorial commentary: COVID-19 as a cardiovascular disease risk factor
- 16 July 2022
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 32 (8) , 476-478
Editorial commentary: COVID-19 as a cardiovascular disease risk factor